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Abstract 
Purpose: mRNA degradation is an important regulatory step for controlling gene expression and 
cell functions. Genetic abnormalities involved in mRNA degradation genes have been found to 
be associated with cancer risk. Therefore, we systematically investigated the roles of genetic 
variants in the general mRNA degradation pathway in lung cancer risk. 
Experimental design:  We performed meta-analyses by using summary data from six lung 
cancer genome-wide association studies (GWASs) from the Transdisciplinary Research in 
Cancer of the Lung and additional two GWASs from Harvard University and deCODE in the 
International Lung Cancer Consortium. Expression quantitative trait loci analysis (eQTL) was 
used for in silico functional validation of the identified significant susceptibility loci. 
Results: This pathway-based analysis included 6,816 single nucleotide polymorphisms (SNP) in 
68 genes in 14,463 lung cancer cases and 44,188 controls. In the single-locus analysis, we found 
that 20 SNPs were associated with lung cancer risk with a false discovery rate threshold of 
<0.05. Among the 11 newly identified SNPs in CNOT6, which were in high linkage 
disequilibrium, the rs2453176 with a RegulomDB score “1f” was chosen as the tagSNP for 
further analysis. We found that the rs2453176 T allele was significantly associated with lung 
cancer risk (odds ratio=1.11, 95% confidence interval=1.04-1.18) in the eight GWASs. In the 
eQTL analysis, we found that levels of CNOT6 mRNA expression were significantly correlated 
with the rs2453176 T allele, which provided additional biological basis for the observed positive 
association. 
Conclusion: The CNOT6 rs2453176 SNP may be a new functional susceptible locus for lung 
cancer risk. 
Introduction 
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Lung cancer is one of the most frequently diagnosed cancers with about 1.8 million new lung 
cancer cases reported in 2012 worldwide, accounting for about 13% of total cancer diagnoses 
[1]. In the United States, 224,390 new lung cancer cases are estimated to occur in 2016 [2]. In 
addition to other factors, such as occupational and environmental carcinogens, cigarette smoking 
is the major risk factor for lung cancer [3,4], but not all smokers develop lung cancer, which 
suggests that genetic predisposition play an essential role in the lung carcinogenesis [5]. 
In recent years, some genome-wide association studies (GWASs) of lung cancer have been 
conducted, and a number of genetic variants, i.e., single nucleotide polymorphisms (SNPs), have 
been found to be associated with lung cancer risk. For example, the significant susceptibility loci 
associated with lung cancer risk include 5p15.3 (rs401681, rs4975616 and rs402710 in 
CLPTM1L and rs2736100 in TERT) [6-11], 6p21.3 (rs3117582 in BAG6 or APOM and 
rs2395185 in HLA-DRB5 or HLA-DRB9) [6,8,9,11], 6q22.1 (rs9387478 in RAP1BP3 or 
DCBLD1) [11] and 15q25.1 (rs8034191 in HYKK and rs1051730 in CHRNA3) [6,8,9,12-15]. 
Among these SNPs, rs1051730, rs3117582 and rs2736100 were found to be specifically 
associated with risk of lung adenocarcinoma (AD) [9], whereas rs12296850 (mapped to 12q23.1) 
in SLC17A8 or NR1H4 was found to be a susceptibility locus for risk of squamous cell 
carcinoma (SC) [16]. Interestingly, the vast majority of the SNPs identified by GWASs are in 
introns or intergenic regions, and their functional evidence is limited.  In the present study, we 
employed the pathway-based strategy that dramatically decreases the number of SNPs to be 
analyzed and thus significantly reduced multiple testing with the aim to identify possible lung 
cancer risk-associated functional SNPs that may have not been revealed by previous lung cancer 
GWASs.  
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The degradation of mRNA is an important regulatory step for controlling gene expression and 
cell functions [17]. The general cytoplasmic mRNA decay pathway usually begins with the 
deadenylation, which removes the poly(A) tail Ccr4-Not complex [18], followed by degradation 
of mRNA proceeding in two directions of 5’-3’ or 3’-5’. The 5’-3’ mRNA degradation initiates 
with decapping N7-methylguanosine (m7G) cap mainly by DCP1/DCP2 proteins and 
subsequently degraded by the exoribonuclease Xrn1, while the 3’-5’ mRNA degradation is 
mainly catalyzed by 10-12 subunit exosome [19,20].  
Some studies suggest that genetic abnormalities of genes involved in the general mRNA 
degradation pathway may be associated with lung cancer. For example, various genetic variants 
in LSM2-LSM8, which encode cofactors for mRNA decapping, were recently found in lung 
cancer cell lines [21]. Therefore, we hypothesize that genetic variants of the general mRNA 
degradation pathway are associated with lung cancer risk. To test the hypothesis, we conducted 
the comprehensive meta-analysis of the eight published lung cancer GWASs from the ILCCO 
(International Lung Cancer Consortium)-TRICL (Transdisciplinary Research in Cancer of the 
Lung) consortia, focusing on the SNPs of the genes in the general mRNA degradation pathway. 
 
Materials and Methods  
Study populations  
The first part of the study populations came from the TRICL consortium, which included 12,160 
lung cancer cases and 16,838 controls (all Europeans) of six previously published GWASs from: 
the MD Anderson Cancer Center (MDACC), the Institute of Cancer Research (ICR), the 
National Cancer Institute (NCI), the International Agency for Research on Cancer (IARC), 
Toronto study from Samuel Lunenfeld Research Institute study (Toronto), and the German Lung 
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Cancer Study (GLC) [22]. The second part of the study populations included GWASs of 
European ancestry from Harvard Lung Cancer Study (984 cases and 970 controls) [23] and 
Icelandic Lung Cancer Study (deCODE) (1,319 cases and 26,380 controls) [15] of the ILCCO. 
Written informed consents were achieved for all participants, and the present study was approved 
by each institutional review board of the participating institutions.  
GWAS genotyping and imputation  
Genotyping in the eight GWASs was performed by Illumina HumanHap 317, 317+240S, 
370Duo, 550, 610 or 1M arrays. The imputation was conducted by IMPUTE2 v2.1.1 or MaCH 
v1.0 software using the reference panel from the 1000 Genomes Project (phase I integrated 
release 3, March 2012). Standard quality control on samples was performed on all scans in the 
analysis, excluding any participants with low call rate (< 90%), extremely high or low 
heterozygosity (P < 1.0×10−4), non-European (with the HapMap phase II CEU, JPT/CHB and 
YRI populations as a reference) and imputed SNPs with an information score < 0.40 in 
IMPUTE2 or r2 < 0.30 in MaCH. 
Gene and SNP selection  
We first identified genes in the general mRNA degradation pathway from the Molecular 
Signatures Database [24] and the literature [18]. Overall, 75 genes located on autosomal 
chromosomes were selected, of which seven genes were pseudogenes or duplicates or withdrawn 
from updated NCBI. As a result, we then extracted genotype data of 68 genes (detailed in Table 
1), including 2-kb of the flanking regions of each gene, from the GWAS datasets that also 
included those SNPs generated by imputation. The final meta-analysis contained 6,816 SNPs and 
covariates provided by the TRICL consortium in the summary data with the following standards: 
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genotyping rate ≥ 90%, minor allele frequency ≥ 1%, and Hardy Weinberg Equilibrium exact 
P value ≥ 10-5. The overall workflow is shown in Figure 1.  
In silico functional validation  
Two in silico tools, SNPinfo (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) [25], 
RegulomeDB (http://regulomedb.org/) [26], were used to predict potential functions. Expression 
quantitative trait loci (eQTL) analysis was performed by using the expression data of 
lymphoblastoid cell lines from 373 Europeans available in the 1000 Genomes Project 
(http://www.1000genomes.org/category/frequently-asked-questions/gene-expression) [27] and 
The Cancer Genome Atlas (TCGA) ( https://tcga-data.nci.nih.gov/tcga/) [28]. In this TCGA 
dataset, 107 subjects had adjacent normal lung cancer samples used for the different expression 
testing, which were matched by 105 adjacent normal cancer tissue samples from the same 
individuals with the genotype data. 
Statistical analysis  
Logistic regression model was used to calculate the odds ratios (ORs) and their 95% confidence 
intervals (CIs) in an additive genetic model with PLINK (v1.06) software. A meta-analysis with 
the inverse variance method was employed on the 6,816 SNPs with Stata software (v12, State 
College, Texas, US). Cochran's Q statistic was applied to test for heterogeneity and the I2 
statistic for the proportion of the total variation in the meta-analysis [29]. The fixed-effects 
model was used when there was no heterogeneity among GWASs (Q-test P > 0.100 and I2 < 
50%); otherwise, the random-effects model was used. Multiple testing correction was conducted 
with false discovery rate (FDR) with a threshold < 0.050 [30]. A linear regression model was 
also performed to evaluate the correlation between SNPs and mRNA expression levels of the 
corresponding genes. A paired t-test was used to compare the mRNA expression levels of genes 
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in the lung cancer and normal adjacent tissue from the TCGA database. LocusZoom 
(http://locuszoom.sph.umich.edu/locuszoom/) was applied to construct regional association plots 
using Europeans from the 1000 Genomes Project as the reference (phase I integrated release 3, 
March 2012) [31]. Haploview v4.2 was used to generate the Manhattan plot and LD plots [32]. 
All analyses were conducted with SAS (version 9.4; SAS Institute, Cary, NC, USA) except for 
those specified otherwise. 
 
Results  
Associations of the SNPs with lung cancer risk  
We first performed a meta-analysis in the TRICL database consisted of six previously published 
GWAS datasets with 12,160 cases and 16,838 controls. The basic information of these six 
studies is presented in Supplemental Table S1. A total of 6,816 SNPs in the pathway were 
extracted, of which 466 SNPs were associated with lung cancer risk at P < 0.05 in the additive 
model and 20 SNPs on LSM2, SKIV2L and CNOT6 remained significantly associated with lung 
cancer risk with FDR < 0.05 after multiple testing corrections (Figure 2A and Table 2). Among 
these SNPs, we excluded those of LSM2 and SKIV2L, because they were mapped to and in high 
LD with previously GWAS-reported locus at 6p21.33 [6,8]. As a result, 11 SNPs of CNOT6 
located at 5q35.3 were left for further analysis. In the LD analysis, these 11 SNPs shared 
moderate to high LD (r2 ≥ 0.60, Figure 2B and 2C). We finally chose rs2453176 as the tag 
SNP, because it was significantly associated with lung cancer risk (OR = 1.13, 95% CI = 1.06-
1.19, P = 4.33×10-5) (Table 2) and potentially functional according to function prediction and its 
imputation quality was the best among the 11 SNPs (Table 3). We used the forest plot to 
illustrate the association between rs2453176 and lung cancer risk in the six GWASs (Figure 3), 
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and the rs2453176 T allele was associated with an increased lung cancer risk in five GWASs, 
except for the GLC GWAS.  
We expanded our analysis to include additional two independent lung cancer GWASs 
(Supplemental Table S1). The deCODE GWAS validated our result of the CNOT6 rs2453176 
tag SNP (OR = 1.14, 95% CI = 1.01-1.28, P = 0.032), while the GWAS from Harvard University 
displayed the same trend as the GLC GWAS (OR = 0.85, 95% CI = 0.68-1.05, P = 0.133) 
(Figure 3 and Table 4).  
As we combined the above results from the eight GWASs, the functional CNOT6 rs2453176 tag 
SNP was found to be significantly associated with an increased risk of lung cancer (OR = 1.11, 
95% CI = 1.04-1.18, P = 0.001) after the FDR correction (Figure 3 and Table 4). 
Stratified analyses by lung cancer histology 
Since lung cancer has different histological types that could have distinct biological behaviors, 
we performed AD and SC subgroup analysis and found that the rs2453176 T allele was 
associated with a borderlinely increased risk in AD (OR = 1.13, 95% CI = 1.00-1.27, P = 0.050, 
Table 4), but it was significantly associated with SC risk (OR = 1.12, 95% CI = 1.03-1.22, P = 
0.006, Table 4). Because smoking is a major risk factor for lung cancer, we further stratified the 
data into smokers and non-smokers and found that that the rs2453176 T allele was associated 
with a significantly increased risk in smokers (OR = 1.09, 95% CI = 1.02-1.17, P = 0.011, Table 
5), while the allele was not statistically significant in non-smokers (OR = 1.10, 95% CI = 0.89-
1.36, P = 0.363, Table 5). Homogeneity tests suggested that there was no heterogeneity between 
strata either in subgroups of histologic types or smoking status (Table 4 and Table 5, all P > 
0.05). 
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Functional validation by eQTL analysis  
Because the CNOT6 rs2453176 SNP was predicted with a score of "1f", suggesting the most 
confident functional annotation by regulomeDB [26], we further explored the underlying 
molecular mechanism by performing the eQTL analysis. With mRNA expression data of 
lymphoblastoid cell lines from 373 Europeans available from the 1000 Genomes Project, We 
found that expected mRNA expression levels of CNOT6 were significantly decreased with an 
increased number of the rs2453176 T allele in both the additive (P = 0.008) (Figure 4A) and 
dominant (P = 0.007) (Figure 4B) models but not the recessive model (Figure 4C).  However, 
only 105 subjects had both DNA and RNA samples tested in this dataset. We also used the 105 
normal adjacent tissue samples in the TCGA to further explore the correlation between the 
rs2453176 genotypes and their corresponding mRNA expression levels, but we did not observe a 
statistical significance (P > 0.05) (Supplemental Figure S1A-S1C).  We also compared the 
mRNA expression level of CNOT6 in the 107 paired samples and did not find a statistically 
significant difference (P > 0.05) (Supplemental Figure S1D). 
 
Discussion 
In the present study, we found that a novel potentially functional susceptibility locus rs2453176 
C>T of CNOT6 in the general mRNA degradation pathway was associated with an increased 
lung cancer risk in 14,463 cases and 44,188 controls. This association was further supported by a 
significant correlation between a decreased mRNA expression level and an increasing number of 
the A allele in the eQTL analysis.  
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Gene expression disorder is one of cancer hallmarks, and instability of mRNA may result in 
altered transcript/protein levels of oncogenes and tumor repressor genes [33]. The degradation of 
mRNA is a key step in controlling the expression of genes related to cell proliferation. For 
example, the CCR4-Not complex consists of highly conserved exoribonucleases and adaptor 
proteins that hydrolyze and shorten the poly(A) tail, which starts the initial and the rate-limiting 
step of mRNA degradation [18,34-36]. Located at 5q35.3, CNOT6 encodes a protein that has a 
3'-5' RNase activity and acts as a catalytic subunit of the CCR4-Not deadenylation complex [37].  
Although it remains unclear how the catalytic subunit works during the deadenylation process, 
some studies reported that its expression level was associated with carcinogenesis or prognosis. 
For example, one study of lung cancer found that the CNOT6 overexpression in lung SC 
predicted a significantly less metastasis [33]. Another study of acute leukemia discovered that 
CNOT6 had a significantly lower expression in patients than in controls [38]. These two studies 
suggest that high expression levels of CNOT6 may promote the degradation of mRNA of some 
oncogenes and the suppression of cell proliferation in carcinogenesis. 
In the present study, we identified that the CNOT6 rs2453176 T allele was associated with an 
increased risk of lung cancer, which was supported by the association of CNOT6 rs2453176 T 
allele with a decreased mRNA expression level in lymphoblastoid cell lines from 373 Europeans. 
This finding is consistent with the role of CNOT6 in lung cancer prognosis as previously 
described [33]. The ENCODE project data from University of California Santa Cruz show that 
the CNOT6 rs2453176 locus is located at the DNase I hypersensitive region (Supplemental 
Figure S2). Usually such an area has a loose chromatin structure and renders it a region with a 
high affinity for transcription factors (TFs). As a result, some TFs, including MAFK and MAFF, 
bond to this region in many cell types (Supplemental Figure S2). For example, MAFK and 
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MAFF were found to form heterodimers with a series of TFs and suppressed gene transcriptions 
[39,40]. Based on these, we speculate that the rs2453176 T allele may have a relatively high 
affinity with MAFK or MAFF and thus leads to the decreased mRNA expression of CNOT6. It is 
likely that a reduced quantity of CNOT6 may not be optimal in the mRNA degradation of some 
aberrant genes, which may in turn increases lung cancer risk, but these speculations need to be 
further investigated. 
In the stratification analysis, rs2453176 was associated with lung cancer risk in both AD and SC 
subtypes, but it was significantly associated with cancer risk in the smokers but not in the non-
smokers. Genetic susceptibility to smoking-related lung cancer risk may determine smoking 
behavior and tobacco metabolism [41]. Indeed, we found that the rs2453176 T allele was 
associated with a higher risk of lung cancer in smokers than in non-smokers. One study reported 
that smoking would enhance the activity of the GATA family [42], and another study reported 
that nicotine would increase the expression of EP300 and promote the lung cancer growth [43]. 
From the Supplemental Figure S2, GATA1, GATA2 and EP300 are the TFs that bind to the 
rs2453176 locus, possibly explaining why carriers of the rs2453176 T allele may have an 
increased risk of lung cancer in smokers than non-smokers.  
There are some limitations in the present study. First, we employed the Molecular Signatures 
Database [24] to define the general mRNA degradation pathway to be investigated, but we may 
have missed some newly discovered genes in the pathway. However, we searched the literatures 
and added genes as many as possible. Second, due to the data limitation, we had no access to 
family history and others factors that may have an impact on lung cancer risk. Third, we used the 
eQTL analyses from lymphoblastoid cell lines and normal adjacent tissue in TCGA database to 
validate the risk association. Although the results from the cell lines support our identified 
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association, they may only reflect the baseline or genetically determined expression levels 
without exposure to smoking. The gene expressions in the normal adjacent lung tissues may be 
in some degree different from the normal lung tissue and did not support the association. 
Overall, the present study of eight published GWASs identified a novel CNOT6 rs2453176 SNP 
in the general mRNA degradation pathway to be significantly associated with lung cancer risk in 
European populations, and the risk was more evident in smokers than in non-smokers. Although 
we used the publically available gene expression database from blood to confirm the biological 
significance of the variant, further functional evaluations in normal lung tissue are warranted to 
validate our findings. 
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Figures and Tables 
Figure 1. Study workflow SNP: single nucleotide polymorphism; FDR: false discovery rate; 
TRICL: Transdisciplinary Research in Cancer of the Lung; GWAS: genome-wide association 
study; eQTL: expression quantitative trait loci. 
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Figure 2. Screening of SNPs in the general mRNA degradation pathway.  A, Manhattan Plot 
of genome-wide association results from the general mRNA degradation pathway in TRICL. The 
x-axis shows SNPs’ positions on each chromosome. The y-axis shows the association P values 
with lung cancer risk (as –log10 P values). The FDR threshold of 0.05 was shown by a 
horizontal blue line. The P value of 0.05 was shown by a horizontal red line. B, Regional 
association plot for SNP rs2453176 in 500 kb up- and downstream region. The left-hand y-axis 
shows P values of the SNPs, which are transformed as −log10 (P) against chromosomal base pair 
positions. The right-hand y-axis shows the recombination rate estimated from HapMap Data Rel 
22/phase II European population; C, The linkage disequilibrium plots of 11 SNPs in CNOT6. 
The value within each diamond represents the pairwise correlation between SNPs (measured as 
r2) defined by the upper left and the upper right sides of the diamond. 
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Figure 3. Forest plots for associations between CNOT6 rs2453176 and lung cancer risk for 
all participants (P = 0.0013). 
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Figure 4. The eQTL analysis of CNOT6 mRNA expression for rs2453176 with 
lymphoblastoid cell data of 373 Europeans from 1000 Genomes Project. A. additive model, 
P = 0.008; B. dominant model, P = 0.007; C. recessive model, P = 0.634. 
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Supplemental Figure S1 A-C. The eQTL analysis of CNOT6 mRNA expressions for 
rs2453176 in the 105 adjacent normal lung cancer tissue samples from the TCGA database.  
A. additive model, P = 0.491, B. dominant model, P = 0.990, C. recessive model, P = 0.667; D, 
The mRNA expression of  CNOT6 in the 107 paired lung cancer and normal adjacent tissue 
samples from the TCGA database (P = 0.237). 
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Supplementary Figure S2.  The ENCODE project data of rs2453176 from UCSC browser 
(NCBI137/hg19). 
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Table 1 The mRNA degradation pathway gene sets 
Dataset Name of pathway 
Gene 
number 
Gene name 
KEGG* KEGG_RNA_DEGRADATIONE 59 C1D, C1DP2**, C1DP3**, CNOT1, CNOT10, CNOT2, CNOT3, 
CNOT4, CNOT6, CNOT6L, CNOT7, CNOT8, DCP1A, DCP1B, DCP2, 
DCPS, DDX6, DIS3, EDC3, EDC4, ENO1, ENO2, ENO3, EXOSC1, 
EXOSC10, EXOSC2, EXOSC3, EXOSC4, EXOSC5, EXOSC6, EXOSC7, 
EXOSC8, EXOSC9, HSPA9, HSPD1, LSM1, LSM2, LSM3, LSM4, 
LSM5, LSM6, LSM7, MPHOSPH6, NAA38, PAPD7, PAPOLA, 
PAPOLB, PAPOLG, PARN, PATL1, PNPT1, RQCD1, SKIV2L, 
SKIV2L2, TTC37, WDR61, XRN1, XRN2, ZCCHC7. 
Reactome REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 48 C2orf29**, CNOT10, CNOT2, CNOT3, CNOT4, CNOT6, CNOT7, 
CNOT8, DCP1A, DCP1B, DCP2, DCPS, DDX6, DIS3, EDC3, EDC4, 
EIF4A1, EIF4A2, EIF4A3, EIF4B, EIF4E, EIF4G1, EXOSC1, 
EXOSC2, EXOSC3, EXOSC4, EXOSC5, EXOSC6, EXOSC7, EXOSC8, 
EXOSC9, LOC645139**, LOC645947**, LOC651789**, 
LOC652607**, LSM1, LSM2, LSM3, LSM4, LSM5, LSM6, PABPC1, 
PAIP1, PARN, PATL1, RQCD1, TNKS1BP1, XRN1. 
Reactome REACTOME_DEADENYLATION_OF_MRNA 22 C2orf29**, CNOT10, CNOT2, CNOT3, CNOT4, CNOT6, CNOT7, 
CNOT8, EIF4A1, EIF4A2, EIF4A3, EIF4B, EIF4E, EIF4G1, 
LOC645139**, LOC651789**, LOC652607**, PABPC1, PAIP1, 
PARN, RQCD1, TNKS1BP1. 
Reactome REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASE 11 DCPS, DIS3, EXOSC1, EXOSC2, EXOSC3, EXOSC4, EXOSC5, 
EXOSC6, EXOSC7, EXOSC8, EXOSC9, 
Reactome REACTOME_MRNA_DECAY_BY_5_TO_3_EXORIBONUCLEASE 15 DCP1A, DCP1B, DCP2, DDX6, EDC3, EDC4, LOC645947, LSM1, 
LSM2, LSM3, LSM4, LSM5, LSM6, PATL1, XRN1. 
PID* NO DATA 0  
GO* NO DATA 0  
BioCarta NO DATA 0  
Literature  2 PAN2, PAN3 
Total  68***  
*KEGG, Kyoto encyclopedia of genes and genomes; GO, gene ontology; PID, pathway interaction database; 
**Pseudo gene: C1DP2, C1DP3, LOC645139; same gene with different name: C2orf29; withdrawn by updated NCBI: LOC645947, LOC651789, LOC652607. 
***After removing the duplicate genes and those genes mentioned  in **; 
Search keyword: mRNA degradation; Search Filters: Collection, canonical pathways + GO gene sets; Organism, Homo sapiens; Contributor, all contributors. 
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Table 2 Associations between SNPs in the general mRNA degradation pathway and lung cancer risk with FDR < 0.050 in TRICL GWASs  
SNP Gene Chr. Position (hg19) Allelea EAF Qb I2 Effectc 
rs115834633 LSM2 6 31765984 G/A 0.11 0.200 30.79 ++++++ 
rs114312980 LSM2 6 31768799 A/C 0.11 0.230 26.77 ++++++ 
rs115801685 LSM2 6 31772093 C/A 0.11 0.220 27.36 ++++++ 
rs115489726 LSM2 6 31766660 C/T 0.11 0.240 25.69 ++++++ 
rs114637560 LSM2 6 31765864 T/A 0.15 0.260 22.42 +-++++ 
rs114984862 SKIV2L 6 31936668 C/T 0.27 0.290 18.64 ++++++ 
rs9800264 CNOT6 5 179940091 G/A 0.10 0.750 0.00 +++++- 
rs2387281 CNOT6 5 179988283 T/C 0.10 0.743 0.00 +++++- 
rs6877400 CNOT6 5 179996111 T/C 0.10 0.747 0.00 +++++- 
rs116188106 SKIV2L 6 31927342 G/A 0.27 0.298 17.82 ++++++ 
rs114011334 SKIV2L 6 31928799 C/T 0.27 0.297 17.92 ++++++ 
rs115002281 SKIV2L 6 31929014 C/A 0.27 0.297 17.95 ++++++ 
rs10052782 CNOT6 5 179975104 C/T 0.10 0.723 0.00 +++++- 
rs6422334 CNOT6 5 179982151 C/T 0.10 0.734 0.00 +++++- 
rs2453176 CNOT6 5 179975792 C/T 0.10 0.723 0.00 +++++- 
rs2387285 CNOT6 5 179982278 A/G 0.10 0.700 0.00 +++++- 
rs2447734 CNOT6 5 179968674 G/C 0.10 0.720 0.00 +++++- 
rs76820754 CNOT6 5 179936737 G/A 0.10 0.735 0.00 +++++- 
rs780126 CNOT6 5 179963034 C/T 0.13 0.758 0.00 +++++- 
rs812956 CNOT6 5 179953048 G/C 0.10 0.653 0.00 +++++- 
SNP: single nucleotide polymorphism; FDR: false discovery rate;  TRICL: Transdisciplinary Research in Cancer of the Lung; GWAS: genome-wide association study; Chr.: chromosome; EAF: effect allele frequency; OR: odds ratio; CI: confidence interval; 
aReference allele/effect allele; 
bFixed effect models were used when no heterogeneity was found between studies (Q-test P > 0.100 and I2 < 50.0%); otherwise, random effect models were used; 
c “+” means a positive association, and “-“ means a negative association. 
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Table 3 Linkage disequilibrium between the 11 SNPs of CNOT6 in European populations included in the 1000 Genomes Project and imputation quality 
scores 
SNP 
Position      
(hg19) 
D' r2 
Function prediction Imputation quality 
SNPinfoa Regulome DBb 
Info 
ICR 
Rsq 
MDACC 
Rsq 
IARC 
Info 
NCI 
Info 
Toronto 
Rsq 
GLC 
rs2453176 179975792   -- 1f 1.000 0.999 1.000 1.000 1.000 1.000 
rs780126 179963034 1.00 0.71 -- -- 0.874 0.751 0.703 0.859 0.857 0.784 
rs2387281 179988283 1.00 0.97 -- -- 0.998 0.972 0.969 0.996 0.990 0.967 
rs6877400 179996111 1.00 0.97 Splicing site 5 0.998 0.964 0.965 0.996 0.990 0.953 
rs2387285 179982278 1.00 0.97 -- 4 0.990 0.966 0.923 0.988 0.981 0.964 
rs812956 179953048 1.00 0.97 -- 6 0.991 0.961 0.962 0.988 0.978 0.976 
rs9800264 179940091 1.00 0.99 -- -- 0.999 0.970 0.977 0.998 0.993 1.000 
rs6422334 179982151 1.00 0.99 -- 5 0.999 0.982 0.976 0.997 0.994 0.979 
rs10052782 179975104 1.00 1.00 -- 6 1.000 0.998 1.000 1.000 1.000 1.000 
rs76820754 179936737 1.00 1.00 -- 6 1.000 0.970 0.971 0.999 0.998 0.999 
rs2447734 179968674 1.00 1.00 -- -- 1.000 0.994 0.999 0.999 0.997 0.999 
SNP: single nucleotide polymorphism; 
Imputation quality: Rsq: MaCH r-squared; Info: IMPUTE2 information score; 
ICR: the Institute of Cancer Research Genome-wide Association Study, UK; 
MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US; 
IARC: the International Agency for Research on Cancer Genome-wide Association Study, France; 
NCI: the National Cancer Institute Genome-wide Association Study, US; 
Toronto: the Samuel Lunenfeld Research Institute Genome-wide Association Study, Toronto, Canada; 
GLC: German Lung Cancer Study, Germany; 
ahttps://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm; 
bhttp://regulomedb.org/. 
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Table 4 Associations between of CNOT6 rs2453176 (C >T) and lung cancer risk stratified by histologic types in all eight lung cancer GWASs from ILCCO-TRICL 
Study 
Overall AD SC P* 
Case Control OR (95% CI) P Case Control OR (95% CI) P Case Control OR (95% CI) P 
ICR 1952 5200 1.15 (1.02-1.28) 0.020 465 5200 1.38 (1.12-1.70) 0.002 611 5200 1.14 (0.95-1.38) 0.158 0.181 
MDACC 1150 1134 1.25 (1.03-1.52) 0.027 619 1134 1.06 (0.92-1.47) 0.206 306 1134 1.45 (1.08-1.94) 0.013 0.102 
IARC 2533 3791 1.14 (1.00-1.29) 0.053 517 2824 1.13 (0.90-1.42) 0.301 911 2968 1.18 (0.98-1.41) 0.081 0.771 
NCI 5713 5736 1.10 (1.01-1.21) 0.025 1841 5736 1.17 (1.03-1.33) 0.016 1447 5736 1.04 (0.91-1.20) 0.543 0.220 
Toronto 331 499 1.12 (0.76-1.63) 0.057 90 499 1.48 (0.83-2.64) 0.186 50 499 1.00 (0.44-2.25) 0.998 0.442 
GLC 481 478 0.93 (0.69-1.26) 0.064 186 478 1.25 (0.86-1.83) 0.240 97 478 0.90 (0.52-1.54) 0.695 0.330 
Discovery combined 12160 16838 1.13 (1.06-1.19) 4.33E-05 3818 15871 1.21 (1.11-1.32) 2.04E-05 3424 16015 1.13 (1.03-1.23) 0.009 0.268 
Harvard 984 970 0.85 (0.68-1.05) 0.133 597 970 0.79 (0.62-1.01) 0.130 216 970 1.08 (0.75-1.56) 0.678 0.164 
deCODE 1319 26380 1.14 (1.01-1.28) 0.032 547 26380 1.02 (0.85-1.21) 0.858 259 26380 1.11 (0.86-1.43) 0.436 0.592 
Replication combined 2303 27350 1.00 (0.75-1.32) 0.098 1144 27350 0.91 (0.71-1.16) 0.449 475 27350 1.10 (0.89-1.36) 0.381 0.252 
Overall 14463 44188 1.11 (1.04-1.18) 0.001 4862 43221 1.13 (1.00-1.27) 0.050 3897 43365 1.12 (1.03-1.22) 0.006 0.905 
GWAS: genome-wide association study; ILCCO: International Lung Cancer Consortium; TRICL: Transdisciplinary Research in Cancer of the Lung; AD, adenocarcinoma; SC, 
squamous cell carcinoma; OR: odds ratio; CI: confidence interval. 
*Homogeneity tests suggest that there is no heterogeneity between the subgroups of AD and SC in each GWAS and overall result (P > 0.05). 
ICR: the Institute of Cancer Research Genome-wide Association Study, UK; 
MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US; 
IARC: the International Agency for Research on Cancer Genome-wide Association Study, France; 
NCI: the National Cancer Institute Genome-wide Association Study, US; 
Toronto: the Samuel Lunenfeld Research Institute Genome-wide Association Study, Toronto, Canada; 
GLC: German Lung Cancer Study, Germany; 
Harvard: Harvard Lung Cancer Study; 
DeCODE: Icelandic Lung Cancer Study. 
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Table 5 Associations between of CNOT6 rs2453176 (C >T) and lung cancer risk stratified by smoking status in six lung cancer 
GWASs from ILCCO-TRICL Consortia 
 
Study  
Smoker Non-smoker P* 
Case Control OR (95% CI) P Case Control OR (95% CI) P 
MDACC 1150 1134 1.25 (1.03-1.52) 0.027      
IARC 2367 2508 1.12 (0.97-1.29) 0.131 159 1253 1.40 (0.94-2.09) 0.096 0.303 
NCI 5342 4336 1.10 (1.00-1.22) 0.058 350 1379 0.99 (0.72-1.37) 0.972 0.540 
Toronto 236 272 1.14 (0.70-1.86) 0.606 95 217 1.13 (0.61-2.11) 0.702 0.983 
GLC 433 258 1.00 (0.67-1.49) 0.995 35 220 1.64 (0.71-3.82) 0.250 0.298 
Harvard 892 809 0.87 (0.70-1.09) 0.221 92 161 0.71 (0.38-1.33) 0.288 0.549 
Overall 10420 9317 1.09 (1.02-1.17) 0.011 731 3230 1.10 (0.89-1.36) 0.363 0.936 
GWAS: genome-wide association study; ILCCO: International Lung Cancer Consortium; TRICL: Transdisciplinary Research in 
Cancer of the Lung; OR: odds ratio; CI: confidence interval. 
MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US; 
IARC: the International Agency for Research on Cancer Genome-wide Association Study, France; 
NCI: the National Cancer Institute Genome-wide Association Study, US; 
Toronto: the Samuel Lunenfeld Research Institute Genome-wide Association Study, Toronto, Canada; 
GLC: German Lung Cancer Study, Germany; 
Harvard: Harvard Lung Cancer Study; 
*Homogeneity tests suggest there is no heterogeneity between the subgroups of smoker and non-smoker in each GWAS and overall 
result (P > 0.05). 
 
 
  
34 
 
Supplemental Table S1 Summary of characteristics in the eight lung cancer genome-wide association studies of the ILCCO-TRICL 
Consortia 
Variable ICR1 MDACC2 IARC3 NCI4 Toronto5 GLC6 Harvard7 deCODE8 
Case 1952 1150 2533 5713 331 481 984 1319 
  AD 465 619 517 1841 90 186 597 547 
  SC 611 306 911 1447 50 97 216 259 
  Smoker  1150 2367 5342 236 433 892  
  Non-smoker   159 350 95 35 92  
Control 5200 1134 3791 5736 499 478 970 26380 
  Smoker  1134 2508 4336 272 258 809  
  Non-smoker   1253 1379 217 220 161  
ILCCO: International Lung Cancer Consortium;TRICL: Transdisciplinary Research in Cancer of the Lung; AD: adenocarcinoma, SC: 
squamous cell carcinoma; 
1 ICR: the Institute of Cancer Research Genome-wide Association Study, UK; 
2 MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US; 
3 IARC: the International Agency for Research on Cancer Genome-wide Association Study, France; 
4 NCI: the National Cancer Institute Genome-wide Association Study, US; 
5 Toronto: the Samuel Lunenfeld Research Institute Genome-wide Association Study, Toronto, Canada; 
6 GLC: German Lung Cancer Study, Germany; 
7 Harvard: Harvard Lung Cancer Study, US; 
8 deCODE: Icelandic Lung Cancer Study, Iceland. 
 
 
